- |||||||||| lithium carbonate ER / Generic mfg.
Journal: Drugs for bipolar disorder. (Pubmed Central) - Apr 9, 2024
After eliminating possible sensitivity, risperidone ranked 1st in elevating fasting serum glucose (SUCRA No abstract available
- |||||||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie, Caplyta (lumateperone) - Intra / Cellular Therapies
FDA event, Retrospective data, Review, Journal: Efficacy and tolerability of FDA-approved atypical antipsychotics for the treatment of bipolar depression: a systematic review and network meta-analysis. (Pubmed Central) - Apr 3, 2024
Sixteen randomized controlled trials with 7234 patients treated by one of the five AAPs (cariprazine, lumateperone, lurasidone, olanzapine, and quetiapine) were included. No abstract available
- |||||||||| lurasidone / Generic mfg.
Journal: Microneedle-Assisted Transdermal Delivery of Lurasidone Nanoparticles. (Pubmed Central) - Mar 28, 2024
The microneedles demonstrated robust preformation in a characterization test evaluating their insertion capacity, mechanical strength, and the uniformity of microneedle arrays, and were able to deliver a dose equivalent to 20 mg oral administration. Therefore, the potential of a transdermal delivery system for lurasidone using microneedles with nanoparticles was demonstrated.
- |||||||||| lurasidone / Generic mfg.
Review, Journal: The Role of Lurasidone in Managing Depressive Symptoms in People with Schizophrenia: A Review. (Pubmed Central) - Mar 28, 2024
The efficacy of lurasidone in treating patients with first-episode psychosis who present with predominant depressive symptoms suggests that this medication may be a valuable treatment option not only for established cases of schizophrenia but also for individuals in the early stages of the illness. The good tolerability of lurasidone is an important factor that may positively influence treatment decisions.
- |||||||||| lithium carbonate ER / Generic mfg.
Trial termination, HEOR: Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies (clinicaltrials.gov) - Feb 15, 2024
P=N/A, N=1037352, Terminated,
Japan Registry of Clinical Trials ID, jRCTs031200338. Completed --> Terminated; Per PI, this study is not a clinical trial and was inadvertently entered in the system
- |||||||||| clozapine / Generic mfg.
A CASE OF CLOZAPINE-INDUCED MYOCARDITIS (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_3263;
Clozapine was changed to lurasidone during hospitalization for symptom monitoring. This case illustrates the importance of a high index of suspicion and the utility of CMR in the timely diagnosis and management of clozapine-induced myocarditis.
- |||||||||| Cyclurad (cycloserine/lurasidone) / NRx Pharma, Alvogen
Enrollment closed, Phase classification, Trial completion date, Trial primary completion date: MBD: NRX-101 for Bipolar Depression With Subacute Suicidal Ideation (clinicaltrials.gov) - Jan 18, 2024
P2/3, N=74, Active, not recruiting,
This case illustrates the importance of a high index of suspicion and the utility of CMR in the timely diagnosis and management of clozapine-induced myocarditis. Recruiting --> Active, not recruiting | Phase classification: P2 --> P2/3 | Trial completion date: Nov 2023 --> Apr 2024 | Trial primary completion date: Sep 2023 --> Feb 2024
- |||||||||| Cyclurad (cycloserine/lurasidone) / NRx Pharma, Alvogen
Trial completion date, Trial primary completion date: SBD-ASIB: NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation (clinicaltrials.gov) - Jan 18, 2024
P3, N=72, Active, not recruiting,
Recruiting --> Active, not recruiting | Phase classification: P2 --> P2/3 | Trial completion date: Nov 2023 --> Apr 2024 | Trial primary completion date: Sep 2023 --> Feb 2024 Trial completion date: Sep 2023 --> Dec 2024 | Trial primary completion date: Jun 2023 --> Dec 2024
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Journal, Adverse events: Oral and long-acting injectable antipsychotic discontinuation and relationship to side effects in people with first episode psychosis: a longitudinal analysis of electronic health record data. (Pubmed Central) - Dec 18, 2023
Among first prescribed antipsychotic medications, discontinuation occurred earlier with haloperidol [hazard ratio (HR)?=?2.78, 95% CI?=?1.69-4.60] and quetiapine (HR?=?1.43, 95% CI?=?1.16-1.80) than with olanzapine...Among antipsychotics prescribed at any point during treatment, lurasidone (HR?=?1.40, 95% CI?=?1.10-1.78) and aripiprazole (HR?=?1.09, 95% CI?=?1.01-1.19) were associated with earlier discontinuation than olanzapine...Later treatment discontinuation associated with clozapine and PP1M could be related to the relative efficacy of these treatments. These findings merit consideration when selecting antipsychotic therapy for people with FEP.
- |||||||||| lurasidone / Generic mfg.
Journal: The Novel Atypical Antipsychotic Lurasidone Affects Cytochrome P450 Expression in the Liver and Peripheral Blood Lymphocytes. (Pubmed Central) - Dec 9, 2023
In conclusion, chronic treatment with lurasidone simultaneously and in the same way influences the expression and activity of CYP2B, CYP2C11, CYP2E1 and CYP3A2 in the liver and peripheral blood lymphocytes of rats. Thus, the lymphocyte cytochrome P450 profile may be utilized as an indicator of the hepatic cytochrome P450 profile in further clinical studies with lurasidone, and lymphocytes may serve as easily available surrogates for examining the impact of new drugs and chronic in vivo treatments on CYP enzyme expression, as well as to estimate drug-drug interactions and toxicity risk.
- |||||||||| lurasidone / Generic mfg.
Journal: Hot "Dissolving" Extrusion of Lurasidone with Natural Liquid Small Molecule for Amorphous Solid Dispersion Based Self-Assembled Submicron Emulsion. (Pubmed Central) - Dec 5, 2023
Thus, the lymphocyte cytochrome P450 profile may be utilized as an indicator of the hepatic cytochrome P450 profile in further clinical studies with lurasidone, and lymphocytes may serve as easily available surrogates for examining the impact of new drugs and chronic in vivo treatments on CYP enzyme expression, as well as to estimate drug-drug interactions and toxicity risk. The strong non-covalent force between VA64 (as emulsifier) and TA (as oil phase)/ water promotes the self-assembly of submicron emulsion and ensures its stability for at least 10
- |||||||||| lurasidone / Generic mfg.
Trial completion date, Trial primary completion date: ELICE_BD: Study of the Efficacy of Lurasidone in Cognitive Functioning in Bipolar Patients (clinicaltrials.gov) - Nov 29, 2023
P3, N=150, Recruiting,
The strong non-covalent force between VA64 (as emulsifier) and TA (as oil phase)/ water promotes the self-assembly of submicron emulsion and ensures its stability for at least 10 Trial completion date: Dec 2023 --> Mar 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
- |||||||||| lurasidone / Generic mfg.
Journal: The impacts of CYP3A4 genetic polymorphism and drug interactions on the metabolism of lurasidone. (Pubmed Central) - Nov 15, 2023
When co-administration of lurasidone with olmutinib in rats, the AUC and AUC of lurasidone were significantly increased by 73.52 % and 69.68 %, respectively, while CL was observably decreased by 43.83 %. In conclusion, CYP3A4 genetic polymorphism and olmutinib can remarkably affect the metabolism of lurasidone.
- |||||||||| lurasidone / Generic mfg.
Journal: Separation and characterization of related substances of Lurasidone hydrochloride by LC-QTOF-MS techniques. (Pubmed Central) - Nov 10, 2023
The process-related substances were further confirmed by NMR spectra determination, and suggestions were proposed to eliminate them. This study highlights the potential for monitoring and controlling related substances during the manufacturing processes, providing valuable insights for process optimization and quality control of Lurasidone hydrochloride.
- |||||||||| lithium carbonate ER / Generic mfg.
Review, Journal: Diagnosis and Treatment of Bipolar Disorder: A Review. (Pubmed Central) - Nov 3, 2023
Bipolar disorder affects approximately 8 million adults in the US. First-line therapy includes mood stabilizers, such as lithium, anticonvulsants, such as valproate and lamotrigine, and atypical antipsychotic drugs, such as quetiapine, aripiprazole, asenapine, lurasidone, and cariprazine.
- |||||||||| lurasidone / Generic mfg.
Journal: Neuroleptic Malignant Syndrome Associated With Lurasidone: A Case Report. (Pubmed Central) - Oct 24, 2023
First-line therapy includes mood stabilizers, such as lithium, anticonvulsants, such as valproate and lamotrigine, and atypical antipsychotic drugs, such as quetiapine, aripiprazole, asenapine, lurasidone, and cariprazine. No abstract available
- |||||||||| clozapine / Generic mfg.
Enrollment open: An Exploratory Analysis of Immune and Inflammatory Response Associated with Clozapine (clinicaltrials.gov) - Oct 5, 2023
P4, N=60, Recruiting,
We piloted this metric in RCTs of several neuropsychiatric indications and drugs, offering a new way to compare AE burden and tolerability among treatments using existing clinical trial information. Not yet recruiting --> Recruiting
- |||||||||| Psychopharmacology for Pediatric Psychosis (East Ballroom (New York Hilton Midtown); Virtual; In-person) - Sep 30, 2023 - Abstract #AACAP2023AACAP_217;
Results Randomized controlled trials generally support the efficacy of second- and third-generation antipsychotic agents (eg, risperidone, aripiprazole, olanzapine, paliperidone, lurasidone) and some traditional neuroleptics (eg, haloperidol, loxapine) in children and adolescents with schizophrenia spectrum disorders...Trials of ziprasidone and asenapine were not superior to placebo for treating schizophrenia in adolescents...Conclusions The choice of which antipsychotic agent to use first is typically based on side-effect profile, patient and family preference, clinician familiarity, and cost. It is best to start with a medication with evidence of efficacy in the pediatric population, except for olanzapine (given the risk for weight gain) and clozapine.
- |||||||||| A clinical case of subdural hematoma caused by a tic-like head banging in a patient with neurodevelopmental disorder () - Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_1132;
Motor tics symptomatology developed at age 13 and were treated with Aripiprazole and Sertraline...Multiple medications were tried to manage tics and obsessive-compulsive symptomatology, but they did not provide any benefit (Clomipramine, Lurasidone and Tetrabenazine).; A routine EEG revealed a right hemisphere asymmetry, and subsequent MRI identified a chronic subdural hematoma in the left hemisphere... This study presents a rare case of subdural hematoma caused by a tic-like head banging.
- |||||||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie, Caplyta (lumateperone) - Intra / Cellular Therapies
Retrospective data, Review, Journal: Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis. (Pubmed Central) - Aug 23, 2023
Olanzapine plus fluoxetine, quetiapine, olanzapine, lurasidone, lumateperone, cariprazine, and lamotrigine were found to be more efficacious than placebo in adults with acute bipolar depression, with good confidence in the evidence, and to differ in their side-effect profiles. These findings can inform evidence-based care and the development of treatment guidelines internationally.
- |||||||||| Caplyta (lumateperone) - Intra / Cellular Therapies
Review, Journal: Antipsychotic-Induced Metabolic Syndrome: A Review. (Pubmed Central) - Aug 21, 2023
In patients with metabolic syndrome, an antipsychotic with less metabolic side effects such as lurasidone, lumateperone, ziprasidone, and aripiprazole should be prioritized...The risk of metabolic syndrome induced by antipsychotics should be early recognized and closely monitored. Primary and secondary prevention of metabolic syndrome or onset of its feature might help reduce the risk of death for patients using antipsychotics.
- |||||||||| fluoxetine / Generic mfg., lurasidone / Generic mfg.
Journal: Lurasidone as add-on to fluoxetine in obsessive-compulsive disorder with comorbid restrictive anorexia: a case report. (Pubmed Central) - Aug 9, 2023
Full remission was reported after 3 months (Y-BOCS scoring ?14) (P?<?0.01). Further longitudinal and real-world effectiveness studies should be implemented to confirm these novel results, to investigate the potential of lurasidone as add-on strategy to SSRI in poor responder OCD patients, including treatment-resistant-OCD (tr-OCD), as well as in improving eating disorder symptomatology, whereas there is comorbidity with AN-r.
- |||||||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
Review, Journal: Cognitive Effects of Lurasidone and Cariprazine: A Mini Systematic Review. (Pubmed Central) - Jul 31, 2023
The pro-cognitive effect of cariprazine is probably explained by its very high affinity for D3 receptors. Head-to-head studies com- paring lurasidone and cariprazine are needed to establish the "first-choice" treatment for cognitive dys- function associated with schizophrenia.
- |||||||||| Journal, Real-world evidence, Real-world: Obsessive-Compulsive, Psychotic, and Autism Dimensions Overlap in Real World: A Case Report. (Pubmed Central) - Jun 27, 2023
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42017078052, identifier: PROSPERO 2017 CRD42017078052. We discuss similarities and differences in the psychopathology of obsessions, compulsions, and stereotypes in the previously mentioned disorders, to underline factors that can help in the differential diagnosis of similar cases, and consequently in the appropriateness of treatment choice.
- |||||||||| lithium carbonate ER / Generic mfg., lurasidone / Generic mfg.
Retrospective data, Journal: The Effect of Lurasidone on Anxiety Symptoms in Patients With Bipolar Depression: A Post Hoc Analysis. (Pubmed Central) - Jun 24, 2023
P3
Improvement in depressive symptoms and reduction in functional impairment were associated with reduction in anxiety symptoms moderated by baseline sleep disturbance during lurasidone treatment. Trial Registration: ClinicalTrials.gov identifiers: NCT00868699 and NCT00868452.
- |||||||||| Lodopin (zotepine) / Astellas, Serlect (sertindole) / Lundbeck, Abbott
Retrospective data, Review, Journal: Antipsychotic-induced akathisia in adults with acute schizophrenia: A systematic review and dose-response meta-analysis. (Pubmed Central) - Jun 19, 2023
We obtained data on all antipsychotics except clozapine and zotepine. In patients with acute exacerbations of chronic schizophrenia, from moderate to high certainty of evidence, our analysis showed that sertindole and quetiapine carried negligible risks for akathisia across examined doses (flat curves), while most of the other antipsychotics had their risks increase initially with increasing doses and then either plateaued (hyperbolic curves) or continued to rise (monotonic curves), with maximum ORs ranging from 1.76 with 95% Confidence Intervals [1.24, 2.52] for risperidone at 5.4
- |||||||||| Clopixol (zuclopenthixol) / Lundbeck
Journal: In silico repurposing of CNS drugs for multiple sclerosis. (Pubmed Central) - Jun 5, 2023
A point that needs further clarification is norepinephrine reuptake inhibition which is not yet fully studied for cariprazine. Tightest interaction modes were observed for zuclopenthixol-S1PL (?G -7.96
- |||||||||| Review, Journal: Mood Stabilizers of First and Second Generation. (Pubmed Central) - May 27, 2023
The article presents clinical experiences with mood stabilizers of the first and second generations and with "insufficient" ones. Further, current suggestions for their use in preventing recurrences of bipolar mood disorder are provided.
- |||||||||| lurasidone / Generic mfg.
Preclinical, Journal: In Vitro Assessment of Compounded Lurasidone Suspensions for Enteral Feeding Tubes. (Pubmed Central) - May 22, 2023
The study demonstrated a practical procedure to prepare 1 and 8?mg/mL lurasidone suspensions that are compatible with commonly used enteral feeding tube materials and dimensions. A beyond-use date of 14-day was established for the suspensions stored at room temperature.
- |||||||||| Journal: Mood Stabilizers: An Overview (Pubmed Central) - May 21, 2023
Classically, lithium carbonate and valproate are the most commonly used medications; however, in addition to lamotrigine, atypical antipsychotics including aripiprazole, quetiapine, and lurasidone are being used in recent years. Theoretically, patients are administered monotherapy; however, it is not uncommon to use combination treatment in clinical practice.
|
